Ashwagandha for Sleep: What the Evidence Shows

Verdict: Moderate. Consistent evidence for improved subjective sleep quality, mainly via anxiety reduction. Effect sizes are modest. The meta-analytic signal is positive.

The claim: ashwagandha reduces stress and improves sleep. Unlike most supplement claims, this one has a meta-analysis behind it, and the meta-analysis is cautiously positive.

The claim, disaggregated

The marketing around ashwagandha typically presents it as a general stress-reducing, sleep-improving adaptogen. This bundles at least two distinct propositions. The first: ashwagandha reduces cortisol and anxiety. The second: this anxiety reduction improves sleep. The first claim has reasonable evidence. The second follows logically from the first, since anxiety and hyperarousal are major maintaining factors in insomnia. Whether ashwagandha has any direct sleep-promoting effect independent of anxiety reduction is less clear and less supported by the available data.

This distinction matters. If ashwagandha works for sleep only through anxiety reduction, then it should help people whose insomnia is driven by stress and anxiety, and should not help people whose insomnia has other drivers (circadian misalignment, chronic pain, sleep apnea, conditioned wakefulness without anxiety). The trials, as we will see, mostly enrolled people with anxiety, which makes it difficult to separate the pathways.

The mechanism

Ashwagandha (Withania somnifera) is classified as an adaptogen, a category with more marketing history than pharmacological precision. The term means a substance that helps the body adapt to stress, which sounds meaningful until you try to define it operationally. The active constituents are withanolides, a group of steroidal lactones. In animal and in vitro studies, withanolides modulate cortisol levels, interact with GABAergic signaling, and influence the hypothalamic-pituitary-adrenal (HPA) axis.

The proposed sleep pathway is indirect: by reducing stress and cortisol, ashwagandha lowers the hyperarousal that prevents sleep onset and maintenance. Elevated cortisol at night is associated with insomnia; reducing it could theoretically improve the transition into sleep. This makes ashwagandha mechanistically different from a direct sedative and more similar to an anxiolytic. The implication is that its usefulness depends on the underlying cause of the sleep problem.

Some preclinical work also suggests that triethylene glycol, a component of ashwagandha, may have direct sleep-inducing properties in animal models. Whether this translates to humans at supplement doses is unknown.

What the trials show

The Cheah meta-analysis is the most comprehensive assessment. It pooled 5 RCTs with 400 total participants and found a significant improvement in overall sleep quality (standardized mean difference -0.59, 95% CI -0.89 to -0.29) [5]. The effect was more pronounced in people with insomnia than in healthy volunteers, and more pronounced at doses of 600mg or higher. An SMD of -0.59 is a moderate effect, comparable to many pharmaceutical interventions and larger than most supplement findings.

The Langade 2019 trial provides the most direct sleep-specific evidence. It enrolled 60 adults with insomnia and randomized them to 300mg KSM-66 ashwagandha extract twice daily or placebo for 10 weeks [1]. The ashwagandha group showed significant improvements in sleep onset latency, total sleep time, sleep efficiency, and Pittsburgh Sleep Quality Index scores. The trial used actigraphy alongside subjective measures, and the actigraphy data corroborated the self-reports. This combination of objective and subjective support is uncommon in supplement research.

The Langade 2021 study ran two parallel RCTs: one in 50 healthy adults and one in 50 insomnia patients [2]. Both groups showed improved total sleep time and sleep quality with ashwagandha. The healthy-volunteer arm is interesting: it suggests an effect even in people without diagnosed insomnia, though the magnitude was smaller.

The Salve trial tested 250-600mg ashwagandha in 60 adults over 8 weeks and found improvements in both stress (Perceived Stress Scale) and sleep quality (Sleep Quality Scale) compared to placebo [3]. Both outcomes improved, but the stress reduction appeared first, consistent with the hypothesis that sleep improvement is secondary to anxiety reduction.

Where the evidence is stronger

In people with anxiety-related sleep disturbance, the evidence is most coherent. The systematic review by Pratte et al. found consistent anxiety reduction across 5 RCTs, with sleep improvement appearing as a downstream effect [4]. If your insomnia is driven by stress, rumination, and nighttime hyperarousal, ashwagandha has a plausible and modestly supported mechanism.

The meta-analytic signal is positive, consistent, and the effect size (-0.59) is in the range that clinicians consider clinically meaningful. Among adaptogenic herbs marketed for sleep, ashwagandha has the strongest evidence.

Where the evidence is weaker

For insomnia without an anxiety component, the evidence is less clear. The trials predominantly enrolled people reporting both anxiety and sleep difficulty. Whether ashwagandha helps someone who sleeps poorly for other reasons, such as circadian misalignment, chronic pain, sleep apnea, or conditioned wakefulness, is not addressed by the current evidence.

The trials are also mostly small (50-60 participants per arm), use proprietary standardized extracts (KSM-66 and Sensoril), and several were funded by extract manufacturers. These are common limitations in supplement research, not unique to ashwagandha, but they temper the confidence. Manufacturer-funded trials with positive results merit more skepticism than independent trials, not because they are necessarily wrong, but because publication bias and study design choices can favor the sponsor’s product.

The longest trial ran 10 weeks. Whether the effect persists, diminishes, or changes with longer use is not known.

The extract standardization question

KSM-66 and Sensoril are proprietary ashwagandha extracts that standardize for withanolide content. KSM-66 is a full-spectrum root extract standardized to a minimum 5% withanolides. Sensoril is a root and leaf extract standardized to a minimum 10% withanolides. These are different products with different chemical profiles, and the trials are not interchangeable between them.

A consumer buying a generic “ashwagandha” product may get neither extract: the withanolide content, the extraction method, and the plant parts used (root only vs. root and leaf) all vary between products. Whether the positive trial results apply to a non-standardized ashwagandha product from an unfamiliar manufacturer is unknown. This is a general problem with herbal supplement research, but it is particularly relevant for ashwagandha because the positive evidence is concentrated in trials using specific branded extracts.

The withanolide content also raises a dose-comparison problem. A “600mg ashwagandha” product with 5% withanolides delivers 30mg of withanolides. The same label on a product with 2% withanolides delivers 12mg. These are meaningfully different doses of the putative active constituent, despite identical-sounding product descriptions. Without standardization, the label does not tell you what you are taking.

Tolerability and safety considerations

Short-term tolerability in the clinical trials is generally good. Common side effects include mild GI disturbance (nausea, diarrhea) and drowsiness, which is arguably an intended effect for a sleep supplement. Rare case reports of liver injury have been documented, though causality is difficult to establish with herbal products because of contamination risks, mislabeling, and concurrent medications.

Ashwagandha may affect thyroid function, increasing thyroid hormone levels. For people with hyperthyroidism or those taking thyroid medication, this interaction is clinically relevant and should be discussed with a prescriber. It may also have immunostimulatory effects, which creates a theoretical concern for people taking immunosuppressants. Pregnant and breastfeeding women are generally advised to avoid it, as safety data in these populations does not exist.

How it compares to CBT-I

CBT-I produces a standardized mean difference of roughly -1.0 to -1.5 for insomnia severity, which is substantially larger than ashwagandha’s -0.59 for sleep quality. CBT-I’s effects are also durable: improvements persist for years after treatment ends, without ongoing use. Ashwagandha’s effects presumably require continued supplementation.

The comparison is not entirely fair, since CBT-I is a structured behavioral intervention delivered over multiple sessions, and ashwagandha is a supplement taken daily. But the comparison is relevant for anyone choosing between them: if your insomnia is chronic and significant, CBT-I has more evidence, larger effect sizes, and durable results. Ashwagandha may be a useful adjunct, particularly for managing the stress component, but it is not a replacement for behavioral treatment.

There is an interesting theoretical overlap between ashwagandha and CBT-I that is worth noting. CBT-I includes a cognitive component that addresses rumination, catastrophic thinking about sleep loss, and nighttime anxiety. Ashwagandha’s proposed mechanism also addresses anxiety-driven hyperarousal. If both interventions target the same maintaining factor (anxiety), they could be complementary: ashwagandha reducing the physiological arousal while CBT-I addresses the cognitive patterns that generate it. This combination has not been studied in a controlled trial, but the hypothesis is consistent with the mechanistic models of both interventions and their shared target of anxiety-driven hyperarousal.

The bottom line

Ashwagandha has the strongest evidence base among the adaptogenic herbs for sleep, and the meta-analytic signal is genuinely positive. The effect appears to work primarily through anxiety and cortisol reduction rather than direct sedation, which means it is most relevant for people whose insomnia has a stress component. If stress is keeping you awake, ashwagandha is a reasonable option to discuss with a pharmacist. If your insomnia has other drivers, the evidence does not strongly apply, and the first-line recommendation remains CBT-I.

If you’re struggling with sleep regularly, speak with a GP or pharmacist before adding supplements or medications. For persistent insomnia, AASM guidelines recommend CBT-I as the first-line treatment. The American Academy of Sleep Medicine has a provider finder at sleepeducation.org.